Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma

Table 1 Basic patient information

Characteristics	Number	Proportion (%)
Gender
Male	45	0.849
Female	8	0.151
Age (yr)
< 50	22	0.415
≥ 50	31	0.585
HBsAg
Positive	45	0.849
Negative	8	0.151
Liver cirrhosis
Yes	48	0.901
No	5	0.099
ECOG grade
0	26	0.491
1	27	0.509
Child-Pugh class
A	42	0.792
B	11	0.208
BCLC stage
B	27	0.509
C	26	0.491
Maximum tumor diameter (cm)
< 5	9	0.169
5-10	18	0.340
> 10	26	0.491
Tumor capsule
Complete	28	0.528
Incomplete	25	0.472
Alpha-fetoprotein (ng/mL)
< 400 ng/mL	23	0.434
≥ 400 ng/mL	30	0.566
Number of tumors
≤ 3	30	0.566
> 3	23	0.434
Vascular invasion
Vp2	5	0.099
Vp3	5	0.099
Vp4	11	0.208
Vv2	6	0.113
Vv3	0	0.000
Extrahepatic metastases
Yes	12	0.226
No	41	0.774
Lymph node metastases
Yes	6	0.113
No	47	0.887

HBsAg: Hepatitis B surface antigen; ECOG: Eastern Cooperative Oncology Group; PVTT: Portal vein tumor thrombus; BCLC: Barcelona Clinic Liver Cancer; Vp2: PVTT in the second-order branches of the portal vein; Vp3: PVTT in the first-order branch of the portal vein; Vp4: PVTT in the main trunk and/or a contralateral portal vein; Vv2: Hepatic vein trunk tumor thrombus.